Proactive Investors - Run By Investors For Investors

Surgical Innovations PLC furthers US reach as losses fall

Following reportedly severe challenges breaking the US market, revenues across ten active states almost doubled.
Surgical Innovations PLC furthers US reach as losses fall
The core strategy remained the sale of keyhole surgery products

Surgical Innovations (LON:SUN) saw losses come down and revenues rise as the group expanded further into the US.

Following reportedly severe challenges breaking the US market, revenues across ten active states almost doubled to £1.54mln a year.

The group entered into a distribution agreement in February to generate sales in US territories not yet covered.

The core strategy of the group remained the sale of laparoscopic, or keyhole, surgery products and the US is the largest market in the world for laparoscopic surgery.

For the year ended 31 December, revenue stood at £5.47mln, compared to £4.03mln in the same period last year, an increase of 36%.

Operating losses in 2015 were £1.98mln down from £9.78mln in 2014, while the loss after tax was £2.03mln, compared to a loss of £9.46mln.

In 2014 the group was hit by significant debt and restructuring expenses.

However gross margin for the year was down to 14% due to inventory reduction.

More than a third of total sales were sourced from existing stock, which adversely affected manufacturing overhead recovery, it reported.

“There remain some challenges in building on the improvements delivered in 2015, not least in sustaining revenue growth to consistently generate positive returns,” said executive chairman Nigel Rogers.

“We believe that we have the opportunities and resources required to achieve this, and look forward with renewed confidence.”

Shares in Surgical Innovations were down by 1.7% to 1.50p.

View full SUN profile View Profile

Surgical Innovations Group Timeline

Related Articles

Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
January 08 2018
The device can now be sold to aid in heart treatment throughout the European Union

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use